New therapeutic approaches to spinal muscular atrophy.

Abstract

Bench to bedside progress has been widely anticipated for a growing number of neurodegenerative disorders. Of these, spinal muscular atrophy (SMA) is perhaps the best poised to capitalize on advances in targeted therapeutics development over the next few years. Several laboratories have achieved compelling success in SMA animal models using sophisticated methods for targeted delivery, repair, or increased expression of the survival motor neuron protein, SMN. The clinical community is actively collaborating to identify, develop, and validate outcome measures and biomarkers in parallel with laboratory efforts. Innovative trial design and synergistic approaches to maximize proactive care in conjunction with treatment with one or more of the promising pharmacologic and biologic therapies currently in the pipeline will maximize our chances to achieve meaningful outcomes for patients. This review highlights recent promising scientific and clinical advances bringing us ever closer to effective treatment(s) for our patients with SMA.

• Authors: Aga Lewelt, Tara M Newcomb, Kathryn J Swoboda
• Journal: Current neurology and neuroscience reports (Curr Neurol Neurosci Rep) Vol. 12 Issue 1 Pg. 42-53 (Feb 2012) ISSN: 1534-6293 [Electronic] United States
• PMID: 22134788 (Publication Type: Journal Article, Review)

Chemical References

• Survival of Motor Neuron 1 Protein
• Survival of Motor Neuron 2 Protein

Topics

• Animals
• Cells, Cultured
• Clinical Trials as Topic
• Disease Models, Animal
• Genotype
• Humans
• Muscular Atrophy, Spinal (genetics, pathology, physiopathology, therapy)
• Phenotype
• Survival of Motor Neuron 1 Protein (genetics, metabolism)
• Survival of Motor Neuron 2 Protein (genetics, metabolism)